Minervax raises €47.4m in Series B funding round for GBS shot
pharmaphorum
DECEMBER 15, 2020
Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through phase 2 clinical trials, as well as manufacturing and regulatory preparation for phase 3. GBS is responsible for nearly half of all life-threatening infections in newborns.
Let's personalize your content